Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Brain tissue and pathology

Topic: Brain proteins, microglia and lab models

Plain-language summary

Background Alzheimer's disease (AD), a neurodegenerative condition and major subtype of dementia, is often preceded by mild cognitive impairment (MCI), a transitional stage before dementia. While cerebrospinal fluid (CSF) biomarkers are widely used for diagnosing AD and MCI, blood-based biomarkers offer the advantage of easier accessibility. This study aimed to compare blood levels of nine biomarkers among healthy controls, patients with MCI, and those with dementia, and to evaluate their potential for predicting AD progression. Objective The aim of our study was to study biomarkers in three groups of elderly people with varying degrees of cognitive decline. Methods The study included 234 participants aged 65 and older with dementia, MCI, or no cognitive impairment. Cognitive function was assessed using the Mini-Mental State Examination scale. Plasma levels of nine biomarkers, including amyloid-β 40 (Aβ 40 ), amyloid-β 42 (Aβ 42 ), KLK-6, NCAM-1, FGF-21, neurogranin, Tau, pTau181, and TDP-43, were measured by multiplex analysis. Results Aβ 42 levels were higher in the MCI group compared to controls (p = 0.002) and in dementia patients compared to those with MCI (p = 0.018). TDP-43 and neurogranin levels were elevated in dementia patients compared to both the MCI group (p < 0.05 and p < 0.01, respectively) and controls (p < 0.05 and p < 0.001, respectively). Neurogranin levels were also higher in the MCI group compared to controls (p < 0.001) and significantly differed between MCI and dementia (p = 0.003). Conclusions Aβ 42 , TDP-43, and neurogranin show potential as blood-based biomarkers for cognitive decline and may provide insight into the pathogenesis of neurodegeneration.

What this study adds

Evidence grade: Low

The record lists 234 participants. In this cross-sectional study of 234 participants, blood levels of TDP-43 and neurogranin were elevated in dementia patients compared to those with MCI and controls. This suggests these blood markers may help distinguish dementia stages, but the study cannot show whether they predict progression over time.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ochneva, A., Zakurazhnaya, V., Zorkina, Y., Abramova, O. V., Ushakova, V. M., Tsurina, A. M., et al. (2025). The increase in TDP-43 and neurogranin blood levels at different stages of cognitive impairment in the elderly people: A cross-sectional study. Journal of Alzheimer s Disease. https://doi.org/10.1177/13872877251350385

Vancouver

Ochneva A, Zakurazhnaya V, Zorkina Y, Abramova OV, Ushakova VM, Tsurina AM, et al. The increase in TDP-43 and neurogranin blood levels at different stages of cognitive impairment in the elderly people: A cross-sectional study. Journal of Alzheimer s Disease. 2025. doi:10.1177/13872877251350385. PMID: 40518820.

BibTeX

@article{ochneva2025-40518820,
  author  = {Ochneva, Aleksandra and Zakurazhnaya, Valeriya and Zorkina, Yana and Abramova, Olga V. and Ushakova, Valeriya M. and Tsurina, Anna M. and Golubeva, Elizaveta and Gurina, Olga Ivanovna and others},
  title   = {{The increase in TDP-43 and neurogranin blood levels at different stages of cognitive impairment in the elderly people: A cross-sectional study}},
  journal = {Journal of Alzheimer s Disease},
  year    = {2025},
  doi     = {10.1177/13872877251350385},
  pmid    = {40518820},
  url     = {https://doi.org/10.1177/13872877251350385}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this cross-sectional study of 234 participants, blood levels of TDP-43 and neurogranin were elevated in dementia patients compared to those with MCI and controls. This suggests these blood markers may help distinguish dementia stages, but the study cannot show whether they predict progression over time.

Study details

How this study scored 39/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 37 of the 96 points it could be judged on, which is 39 of 100. Total 39 of 100.37 of the 96 points we could judge = 39 of 100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 37 of the 96 points we could judge it on, which is 39 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease)
Journal's citation record 2 / 4 Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 234 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 1 / 3 Lomonosov Moscow State University: institution h-index 708 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40518820)
Free to read 0 / 2 Behind a paywall — scores zero
Points 37 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 37 of the 96 points we could judge it on is 39 out of 100.
Total 39 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.

Related studies in Brain tissue and pathology from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain tissue and pathology

See all studies in Brain tissue and pathology →